Medications for Hyperuricemia
For patients with gout, start allopurinol at a low dose (≤100 mg/day, even lower if CKD stage ≥3) and titrate upward every 2-4 weeks to reach a serum urate target of <6 mg/dL (<5 mg/dL for severe gout with tophi). 1
Key Principle: Treat Gout, Not Asymptomatic Hyperuricemia
Do not initiate urate-lowering therapy (ULT) for asymptomatic hyperuricemia (serum urate >6.8 mg/dL without prior gout flares or tophi). The number needed to treat is 24 patients for 3 years to prevent a single gout flare, making the risks and costs outweigh benefits for most patients. 1
First-Line Medication: Allopurinol
Allopurinol is the strongly recommended first-line agent for all patients with gout, including those with moderate-to-severe chronic kidney disease (CKD stage ≥3). 1, 2
Allopurinol Dosing Strategy:
- Starting dose: ≤100 mg/day (≤50 mg/day in CKD stage ≥3)
- Titration: Increase by 100 mg increments every 2-4 weeks
- Maximum dose: Up to 800 mg/day (FDA-approved maximum)
- Target: Serum urate <6 mg/dL (or <5 mg/dL for severe gout with tophi, chronic arthropathy, or frequent attacks) 1, 2
The low starting dose mitigates the risk of allopurinol hypersensitivity syndrome and reduces flare risk during ULT initiation. 1
Second-Line Options
Febuxostat
- Use when: Allopurinol target not achieved at maximum dose, or allopurinol not tolerated
- Starting dose: ≤40 mg/day with subsequent titration
- Advantage: Can be used in moderate-to-severe CKD (preferred over probenecid in CKD stage ≥3) 1, 2
- Note: Recent Chinese guidelines suggest febuxostat as first-line for asymptomatic hyperuricemia in specific populations, though this contradicts ACR/EULAR recommendations 3
Probenecid (Uricosuric)
- Starting dose: 500 mg once to twice daily with titration
- Contraindication: Moderate-to-severe CKD (stage ≥3) - use allopurinol or febuxostat instead 1
- Use when: Normal kidney function and allopurinol/febuxostat not tolerated or ineffective
Combination Therapy
If serum urate target cannot be reached with allopurinol alone at appropriate doses, either:
- Switch to febuxostat, OR
- Switch to a uricosuric, OR
- Combine allopurinol with a uricosuric 2
Third-Line: Pegloticase
Strongly recommended AGAINST as first-line therapy. 1
Reserved exclusively for crystal-proven severe debilitating chronic tophaceous gout with poor quality of life when serum urate target cannot be reached with any other available drug at maximal dosage (including combinations). 2
Essential Flare Prophylaxis
All patients starting ULT must receive prophylaxis for the first 6 months to prevent gout flares triggered by crystal dissolution:
- First choice: Colchicine 0.5-1 mg/day (reduce dose in renal impairment)
- Alternative: Low-dose NSAIDs if colchicine contraindicated or not tolerated 2
Critical caveat: Avoid co-prescribing colchicine with strong P-glycoprotein or CYP3A4 inhibitors due to neurotoxicity/muscular toxicity risk, especially in patients with renal impairment or on statins. 2
Monitoring and Maintenance
- Target serum urate: <6 mg/dL for all patients; <5 mg/dL for severe gout until crystal dissolution
- Avoid: Long-term serum urate <3 mg/dL 2
- Duration: Lifelong maintenance once target achieved 2
Special Populations
Chronic Kidney Disease
- Adjust allopurinol maximum dose to creatinine clearance
- If target not achieved, switch to febuxostat or benzbromarone (except if eGFR <30 mL/min) 2
- Both allopurinol and febuxostat are preferred over probenecid in CKD stage ≥3 1
Young Patients or High-Risk Features
Consider ULT initiation early (close to first diagnosis) in patients:
- Age <40 years at gout onset
- Serum urate >8.0 mg/dL (480 μmol/L)
- Comorbidities: renal impairment, hypertension, ischemic heart disease, heart failure 2
Common Pitfalls to Avoid
- Starting at high doses: Always start low and titrate to avoid triggering flares and hypersensitivity reactions
- Treating asymptomatic hyperuricemia: No mortality/morbidity benefit demonstrated; avoid unnecessary treatment
- Inadequate prophylaxis: Failure to provide 6 months of flare prophylaxis leads to poor adherence
- Stopping at 300 mg allopurinol: Many patients require >300 mg/day to reach target; titrate up to 800 mg if needed 1
- Using probenecid in CKD: Ineffective and potentially harmful in moderate-to-severe renal impairment